Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid® prescribing: a descriptive analysis
International Journal of Clinical Pharmacy · 2025
DOI: 10.1007/s11096-024-01852-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy, 2025. Verfasst von Alina Stoiber und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Applied Sciences and Public Health, Robert Gordon University, Garthdee Road, Aberdeen, AB10 7QB, Scotland, UK. Hauptthemen laut MEDLINE: Pharmacists, COVID-19 Drug Treatment, Ritonavir, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Paxlovid® (nirmatrelvir and ritonavir) is the only licensed oral antiviral for COVID-19. Ritonavir is a potent inhibitor of cytochrome P450 enzymes causing numerous drug-drug interactions (DDIs). AIM: To describe the frequency, type, and severity of detected drug related problems (DRPs) associated with Paxlovid®. METHOD: This study involved a retrospective quantitative analysis including all patients prescribed Paxlovid® at a public hospital in Vienna, Austria. Data were collected from the patients' records by a clinical pharmacist. A customised, piloted data collection form was used. A sample of data was checked for consistency by an independent clinical pharmacist. Any DDI and severity classification was recorded using an established interaction checker tool. Dosage adjustments due to renal impairment were recorded. RESULTS: One hundred twenty-two of 140 patients (87.1%) required interventions to prevent DRPs. Pharmacists' intervention at dispensing was needed in 63.6% (n = 89) of cases. In 3 (2.1%) patients, Paxlovid® was prescribed despite being contraindicated due to severe renal impairment. The most common were DDIs (n = 80; 57.1%). Renal impairment and DDIs were noted in 24.3% (n = 34) of cases. A total of 313 DDIs were recorded in 114 (81.4%) patients, with severe interactions in 24 (17%) patients. CONCLUSION: Pharmacists' involvement in prescribing highly interacting drugs such as Paxlovid® is essential to enhance patient safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Applied Sciences and Public Health, Robert Gordon University, Garthdee Road, Aberdeen, AB10 7QB, Scotland, UK.
- Hospital Pharmacy, Clinic Hietzing, Vienna Healthcare Group, Vienna, Austria.
- Karl Landsteiner Institute for Clinical Risk Management, Vienna, Austria.
- School of Pharmacy, Applied Sciences and Public Health, Robert Gordon University, Garthdee Road, Aberdeen, AB10 7QB, Scotland, UK. a.tonna@rgu.ac.uk.
Zitieren
APA
Stoiber, A., Gray, G., Sailer, G., Huf, W., & Tonna, A. (2025). Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid® prescribing: a descriptive analysis. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-024-01852-5
Vancouver
Stoiber A, Gray G, Sailer G, Huf W, Tonna A. Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid® prescribing: a descriptive analysis. International Journal of Clinical Pharmacy. 2025. doi:10.1007/s11096-024-01852-5
BibTeX
@article{Stoiber2025,
author = {Stoiber, Alina and Gray, Gwen and Sailer, Gudrun and Huf, Wolfgang and Tonna, Antonella},
title = {Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid® prescribing: a descriptive analysis},
journal = {International Journal of Clinical Pharmacy},
year = {2025},
doi = {10.1007/s11096-024-01852-5}
}
EUVIMED